CO6801638A2 - Moléculas de unión biespecíficas que se unen a dll4 y ang2 - Google Patents

Moléculas de unión biespecíficas que se unen a dll4 y ang2

Info

Publication number
CO6801638A2
CO6801638A2 CO13230710A CO13230710A CO6801638A2 CO 6801638 A2 CO6801638 A2 CO 6801638A2 CO 13230710 A CO13230710 A CO 13230710A CO 13230710 A CO13230710 A CO 13230710A CO 6801638 A2 CO6801638 A2 CO 6801638A2
Authority
CO
Colombia
Prior art keywords
ang2
binding molecules
bispecific binding
bind dll4
dll4
Prior art date
Application number
CO13230710A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44314095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6801638(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6801638A2 publication Critical patent/CO6801638A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CO13230710A 2011-04-01 2013-09-27 Moléculas de unión biespecíficas que se unen a dll4 y ang2 CO6801638A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11160920 2011-04-01

Publications (1)

Publication Number Publication Date
CO6801638A2 true CO6801638A2 (es) 2013-11-29

Family

ID=44314095

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13230710A CO6801638A2 (es) 2011-04-01 2013-09-27 Moléculas de unión biespecíficas que se unen a dll4 y ang2

Country Status (23)

Country Link
US (1) US20130078247A1 (cg-RX-API-DMAC7.html)
EP (1) EP2694545B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014511682A (cg-RX-API-DMAC7.html)
KR (1) KR20140016345A (cg-RX-API-DMAC7.html)
CN (2) CN106046167A (cg-RX-API-DMAC7.html)
AP (1) AP2013007086A0 (cg-RX-API-DMAC7.html)
AR (1) AR085919A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012234218A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013025294A2 (cg-RX-API-DMAC7.html)
CA (1) CA2827809A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013002622A1 (cg-RX-API-DMAC7.html)
CO (1) CO6801638A2 (cg-RX-API-DMAC7.html)
EA (1) EA201301109A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012996A (cg-RX-API-DMAC7.html)
MA (1) MA35233B1 (cg-RX-API-DMAC7.html)
MX (1) MX337115B (cg-RX-API-DMAC7.html)
PE (1) PE20141157A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013502031A1 (cg-RX-API-DMAC7.html)
SG (1) SG193557A1 (cg-RX-API-DMAC7.html)
TN (1) TN2013000389A1 (cg-RX-API-DMAC7.html)
TW (2) TWI551612B (cg-RX-API-DMAC7.html)
UY (1) UY33997A (cg-RX-API-DMAC7.html)
WO (1) WO2012131076A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
HUE044263T2 (hu) * 2012-03-30 2019-10-28 Boehringer Ingelheim Int ANG2-kötõ molekulák
WO2014049100A1 (en) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
CN106459960A (zh) 2014-05-13 2017-02-22 生物蛋白有限公司 条件活性生物蛋白
CN107540747B (zh) * 2017-08-09 2020-01-24 苏州大学附属儿童医院 抗人dll4单克隆抗体6f12
CN110950967B (zh) * 2019-12-13 2022-05-13 山东民康生物科技有限公司 抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
CN118251412A (zh) * 2021-09-10 2024-06-25 海南康哲维盛科技有限公司 抗ang2抗体及其制备方法和应用
CN116444675B (zh) * 2023-05-11 2023-12-22 亲和(武汉)生命科技有限责任公司 一种Pfu DNA聚合酶纳米抗体及其制备方法和应用
WO2025111816A1 (en) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Multispecific fusion proteins targeting angiogenic, inflammatory, and/or fibrotic factors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
EP1983055A1 (en) 2000-04-12 2008-10-22 Human Genome Sciences, Inc. Albumin fusion proteins
EP2316951A1 (en) 2001-01-17 2011-05-04 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
MXPA05007151A (es) 2002-12-31 2005-09-21 Nektar Therapeutics Al Corp Polimeros terminados en maleimida hidroliticamente estables.
DE602004017726D1 (de) 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
DK1888641T3 (da) * 2005-05-18 2012-04-23 Ablynx Nv Serumalbuminbindende proteiner
EP1962895B2 (en) * 2005-12-16 2016-01-20 Regeneron Pharmaceuticals, Inc. THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH
AR061245A1 (es) * 2006-06-06 2008-08-13 Genentech Inc Composiciones y metodos para la modulacion del desarrollo vascular
UA94464C2 (ru) * 2006-06-06 2011-05-10 Дженентек, Инк. Выделенное антитело к dll4 и его применение
NZ572177A (en) * 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CA2663042A1 (en) * 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
NO347649B1 (no) * 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
AU2008234248C1 (en) * 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
WO2009095489A2 (en) 2008-02-01 2009-08-06 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
DE112009000507T5 (de) 2008-03-05 2011-02-10 Ablynx Nv Neue Antigen-bindende Dimerkomplexe, Verfahren zu ihrer Herstellung und ihre Verwendung
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
MX2011002837A (es) * 2008-09-19 2011-07-29 Medimmune Llc Anticuerpos dirigidos al ligando tipo delta 4 (dll4) y usos de los mismos.
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) * 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110195494A1 (en) * 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2

Also Published As

Publication number Publication date
SG193557A1 (en) 2013-11-29
AU2012234218A1 (en) 2013-09-05
BR112013025294A2 (pt) 2017-06-13
CN103596977A (zh) 2014-02-19
KR20140016345A (ko) 2014-02-07
CN103596977B (zh) 2016-07-06
JP2014511682A (ja) 2014-05-19
WO2012131076A1 (en) 2012-10-04
CA2827809A1 (en) 2012-10-04
AP2013007086A0 (en) 2013-08-31
EP2694545B1 (en) 2016-08-24
CN106046167A (zh) 2016-10-26
PE20141157A1 (es) 2014-09-24
US20130078247A1 (en) 2013-03-28
MX2013011032A (es) 2013-12-06
MA35233B1 (fr) 2014-07-03
TWI535735B (zh) 2016-06-01
ECSP13012996A (es) 2013-12-31
EA201301109A1 (ru) 2014-08-29
AR085919A1 (es) 2013-11-06
PH12013502031A1 (en) 2013-12-16
NZ614243A (en) 2015-04-24
MX337115B (es) 2016-02-12
CL2013002622A1 (es) 2014-02-14
TWI551612B (zh) 2016-10-01
UY33997A (es) 2012-09-28
TW201302789A (zh) 2013-01-16
EP2694545A1 (en) 2014-02-12
TW201302797A (zh) 2013-01-16
TN2013000389A1 (en) 2015-01-20

Similar Documents

Publication Publication Date Title
CO6801639A2 (es) Moléculas de unión biespecíficas que se unen a vegf y ang2
CO6801638A2 (es) Moléculas de unión biespecíficas que se unen a dll4 y ang2
CO6811817A2 (es) Moléculas biespecíficas de unión a antígeno de células t
CL2015001988A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
EP2723379A4 (en) ANTI-ALPHA-SYNUCLEIN BINDING MOLECULES
CO6970560A2 (es) Moléculas que se unen a cd3 capaces de unirse a cd3 humano y no humano
FI3485903T3 (fi) Vegf/dll4 -sitovat aineet ja niiden käyttö
CO7020848A2 (es) Anticuerpos que se unen a ox40 y sus usos
PT3202421T (pt) Emulsões de o/a que compreendem alcanos semifluorados
BR112013025208A2 (pt) moléculas de ligação a cd-37 e imunoconjugados das mesmas
BR112014020304A2 (pt) agentes terapêuticos que se ligam a eritrócitos
IL230553A0 (en) Bispecific antigen binding molecules
DK2797957T3 (da) Bindingsmolekyler specifikke for her3 og anvendelser deraf
ECSP14005992A (es) Proteinas que pueden unirse a la il-1
ES2643397T3 (es) Anticuerpos que se unen con integrina alfa-v beta-8
IL229633A0 (en) Combination comprising umeclidinium and a corticosteroid
EP2677963A4 (en) IMPLEMENTATION WITH A NONLINEAR HEAD
BR112013012008A2 (pt) um processo para inibidor seletivo da ciclo-oxigenase-2
EP2701889A4 (en) Bonding process
EP2762586A4 (en) THERMALLY AGED STEEL
EP2808178A4 (en) TIRE REINFORCEMENT ELEMENT AND AIR TIRES THEREWITH
BR112017006626A2 (pt) novas moléculas de ligação que se ligam a l1
BR302012003615S1 (pt) Configuração aplicada a fecho aperta-juntas
ES1076095Y (es) Cierre de presion graduable para pendientes de senora
FR2991858B1 (fr) Goupillon a longueur reductible